Novo Nordisk Profit Margins 2006-2018 | NVO

Current and historical gross, operating and net profit margins for Novo Nordisk (NVO) over the last 10 years. The current net profit margin for Novo Nordisk (NVO) as of March 31, 2018 is 35.21%.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.695B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.643B 16.13
Pfizer (PFE) United States $222.220B 13.67
Novartis AG (NVS) Switzerland $190.657B 16.36
Merck (MRK) United States $168.566B 15.07
AbbVie (ABBV) United States $141.090B 14.39
Sanofi (SNY) France $106.218B 13.44
GlaxoSmithKline (GSK) United Kingdom $103.814B 14.19
Eli Lilly (LLY) United States $96.028B 19.07
AstraZeneca (AZN) United Kingdom $94.148B 9.86
Bristol-Myers Squibb (BMY) United States $92.695B 18.23